1. WHO. COVID-19 weekly epidemiological update, 29 Jun 2022. World Health Organization. 2022; Edition 98.
2. Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, et al. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Molecular Cell. 2020; 79 (5): 710-27. [
DOI:10.1016/j.molcel.2020.07.027]
3. Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ. 2020; 98 (7): 495-504. [
DOI:10.2471/BLT.20.253591]
4. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020:2020.12.21.20248640. [
DOI:10.1101/2020.12.21.20248640]
5. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv. 2021:2020.12.30.20249034. [
DOI:10.1101/2020.12.30.20249034]
6. Salehi-Vaziri M, Fazlalipour M, Seyed Khorrami SM, Azadmanesh K, Pouriayevali MH, Jalali T, et al. The ins and outs of SARS-CoV-2 variants of concern (VOCs). Arch Virol. 2022; 167 (2): 327-44. [
DOI:10.1007/s00705-022-05365-2]
7. Naveca F, da Costa C, Nascimento V, Souza V, Corado A, Nascimento F, et al. SARS-CoV-2 reinfection by the new
8. Variant of Concern (VOC) P. 1 in Amazonas, Brazil. virological org Preprint available at: https://virological org/t/sars-cov-2-reinfection-by-thenew-variant-of-concern-voc-p-1-in-amazonas-brazil/596 Available at: https://virological org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596. 2021.
9. Ferreira I, Datir R, Papa G, Kemp S, Meng B, Rakshit P, et al. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. bioRxiv. 2021: 2021.05.08.443253.
10. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9: e61312. [
DOI:10.7554/eLife.61312]
11. Lu R, Niu P, Zhao L, Wang H, Wang W, Tan W. Sequencing the complete genome of COVID-19 virus from clinical samples using the Sanger Method. China CDC Wkly. 2020;2 (25): 447-52. [
DOI:10.46234/ccdcw2020.088]
12. Salehi-Vaziri M, Jalali T, Farahmand B, Fotouhi F, Banifazl M, Pouriayevali MH, et al. Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. Eur J Clin Microbiol Infect Dis. 2021; 40 (8): 1713-9. [
DOI:10.1007/s10096-021-04221-6]
13. Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19 (3): 141-54. [
DOI:10.1038/s41579-020-00459-7]
14. wwwgovuk [Internet]2020. [cited 2020]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961299/Variants_of_Concern_VOC_Technical_Briefing_6_England-1.pdf.
15. Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol. 2020; 94 (13): e00647-20. [
DOI:10.1128/JVI.00647-20]
16. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584 (7821): 457-62. [
DOI:10.1038/s41586-020-2550-z]
17. Bohn MK, Mancini N, Loh TP, Wang C-B, Grimmler M, Gramegna M, et al. IFCC interim guidelines on molecular testing of SARS-CoV-2 infection. Clin Chem Lab Med. 2020; 58 (12): 1993-2000. [
DOI:10.1515/cclm-2020-1412]
18. Vogels C, Fauver J, Grubaugh N. Multiplexed RT-qPCR to screen for SARS-COV-2 B. 1.1. 7. B.1:1.
19. Bozidis P, Tsaousi ET, Kostoulas C, Sakaloglou P, Gouni A, Koumpouli D, et al. Unusual N Gene Dropout and Ct Value Shift in Commercial Multiplex PCR Assays Caused by Mutated SARS-CoV-2 Strain. Diagnostics. 2022; 12 (4): 973. [
DOI:10.3390/diagnostics12040973]
20. Wollschläger P, Todt D, Gerlitz N, Pfaender S, Bollinger T, Sing A, et al. SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a commercial multiplex PCR assay. Clin Microbiol Infect. 2021; 27 (9): 1353.e1-.e5. [
DOI:10.1016/j.cmi.2021.05.025]
21. Sánchez-Calvo JM, Alados Arboledas JC, Ros Vidal L, de Francisco JL, López Prieto MD. Diagnostic pre-screening method based on N-gene dropout or delay to increase feasibility of SARS-CoV-2 VOC B.1.1.7 detection. Diagn Microbiol Infect Dis. 2021; 101 (4): 115491. [
DOI:10.1016/j.diagmicrobio.2021.115491]
22. Jung Y, Park G-S, Moon JH, Ku K, Beak S-H, Lee C-S, et al. Comparative Analysis of Primer-Probe Sets for RT-qPCR of COVID-19 Causative Virus (SARS-CoV-2). ACS Infect Dis. 2020; 6 (9): 2513-23. [
DOI:10.1021/acsinfecdis.0c00464]
23. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018; 34 (23): 4121-3. [
DOI:10.1093/bioinformatics/bty407]